Vertex chief earned $13.4M in '11

Former Vertex Pharmaceuticals ($VRTX) CEO Matthew Emmens left the chief executive position after reaping $13.4 million in total compensation last year, according to the Boston Business Journal. Despite the fact that Emmens was widely credited with ushering the biotech through a major transition--winning an approval on a game-changing new hepatitis C treatment--the earnings reflect a drop from the $14.9 million in compensation he received for 2010. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.